Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors
August 08 2023 - 3:05PM
Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company
leveraging novel next-generation sequencing (NGS) and multiomics
technologies to empower researchers and clinicians, today announced
the appointment of Marcia Eisenberg, Ph.D., to the Company’s Board
of Directors. Dr. Eisenberg currently serves as Senior Vice
President and Enterprise Chief Scientific Officer at Labcorp (NYSE:
LH) and brings more than 30 years of experience with molecular
genetics, DNA testing, biotechnology, and molecular oncology.
“Marcia’s deep and diverse genomics expertise will be an asset
to Singular as we drive our business strategy forward, and we are
delighted to welcome her to the Board of Directors,” said Drew
Spaventa, Chairman and Chief Executive Officer of Singular
Genomics. “Her extensive experience in applying new technologies to
impact precision medicine at scale complements our mission to
innovate next-generation sequencing and multiomics platforms that
empower researchers and clinicians.”
Since 2014, Dr. Eisenberg has served as Chief Scientific Officer
of Labcorp Diagnostics and more recently was appointed as Labcorp’s
Enterprise Chief Scientific Officer. She served in a variety of
other roles at Labcorp and its affiliates starting in 1990. Dr.
Eisenberg has extensive experience with forensic DNA testing,
biotechnology, molecular genetics, and molecular oncology. She has
helped lead the development and validation of well over a thousand
clinical assays used for patient care during her more than 30-year
tenure at Labcorp. Dr. Eisenberg previously held roles on the
National Institute of Environmental Health Sciences and the Federal
Bureau of Investigation’s DNA Advisory Board, where she was later
recognized for her contributions to the advancement of DNA
technology. A molecular biologist by training, Dr. Eisenberg was a
member of the team responsible for commercializing polymerase chain
reaction (PCR) tests in the 1990s, making large-scale testing
possible. Dr. Eisenberg has been recognized multiple times in her
career including as a Healthcare Businesswomen’s Association
Luminary in 2021, as one of Fierce Healthcare’s 2021 Women of
Influence, and as one of the Fierce Healthcare’s Fiercest Women in
Life Sciences in 2022. Dr. Eisenberg received her B.S. degree in
Biology and her B.A. degree in Psychology from the State University
of New York at Albany, her M.S. degree in Molecular Biology from
the State University of New York at Albany, and her Ph.D. in
Molecular Biology from the University of Kentucky.
“I have been impressed by Singular Genomics’ growth and progress
in launching a sequencing platform that I believe is uniquely
positioned to positively impact many critical applications,” said
Dr. Eisenberg. “Drew and the rest of the leadership team have the
strategic vision, collaborative spirit, and underlying technology
needed to succeed and lead in the next-generation sequencing and
multiomics space, and I am proud to contribute as a board
member.”
About Singular Genomics Systems, Inc. Singular
Genomics is a life science technology company that develops
next-generation sequencing and multiomics technologies. The
commercially available G4 Sequencing Platform is a powerful, highly
versatile benchtop genomic sequencer designed to produce fast and
accurate results. In development, the PX system leverages
Singular’s proprietary sequencing technology, applying it as an in
situ readout to look at RNA and proteins in single cells and
tissue. With these products, Singular Genomics’ mission is to
empower researchers and clinicians to advance science and medicine.
Visit www.singulargenomics.com for more information.
Forward-Looking Statements Certain statements
contained in this press release, other than historical information,
constitute forward-looking statements within the meaning of the
federal securities laws. Forward-looking statements include and are
not limited to quotes from management and statements regarding our
ability to successfully manufacture and commercialize the G4 in
accordance with our timelines, objectives, and specifications. Any
such forward-looking statements are based on our management’s
current expectations and are subject to risks and uncertainties
that could cause our actual future results to differ materially
from our management’s current expectations or those implied by our
forward-looking statements. These risks and uncertainties include
and are not limited to our limited history of manufacturing and
commercializing our products or technology, and the risk factors
described in more detail in our most recent filings on Forms 10-K
and 10-Q and in other filings that we make with the SEC from time
to time. Accordingly, you should not rely on forward-looking
statements as predictions of future events or our future
performance. Except as required by law, we undertake no obligation
to update publicly or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances, or otherwise.
Investor Contact
Matt
Clawson949-370-8500ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB973-271-6085dan@1abmedia.com
Singular Genomics Systems (NASDAQ:OMIC)
Historical Stock Chart
From Apr 2024 to May 2024
Singular Genomics Systems (NASDAQ:OMIC)
Historical Stock Chart
From May 2023 to May 2024